Dahl, Anne Sofie A.
Sørensen, Victor http://orcid.org/0000-0002-0253-7544
Ambrosen, Karen S. http://orcid.org/0000-0002-5638-2357
Sørensen, Mikkel E.
Mohr, Grímur H.
Nielsen, Mette Ø.
Bojesen, Kirsten B. http://orcid.org/0000-0002-7996-3154
Glenthøj, Birte Y. http://orcid.org/0000-0003-3056-7262
Hahn, Margaret http://orcid.org/0000-0001-8884-9946
Midtgaard, Julie http://orcid.org/0000-0003-2381-2127
Ebdrup, Bjørn H.
Funding for this research was provided by:
Lundbeckfonden (R377-2021-340)
Article History
Received: 25 May 2023
Accepted: 6 October 2023
First Online: 7 November 2023
Competing interests
: A.D. was funded by a scholarship from the Lundbeck Foundation. K.B. received a lecture fee from Lundbeck Pharma A/S. B.G. has been the leader of the Lundbeck Foundation Center of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009–December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and are administrated by them. She has no other conflicts to disclose. M.H. received speaker and advisory board fees from Alkermes. She has also received funding to support visiting professorships to Denmark from the Novo Nordisk Fonden, and the Danish Diabetes Association. B.E. is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. The Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS is funded by Lundbeck Foundation grant number R25-A2701. The other authors declare no conflict of interest.